Teva (TEVA) Patent '413 on Capaxone Also Invalidated by U.S.

August 24, 2016 3:41 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

The U.S. Patent Office ruled that Teva Pharma's (NYSE: TEVA) patent '413 on Capaxone claims 1-20 are unpatentable. Earlier claims on its '250 patent were ruled unpatentable.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Hot Corp. News, Litigation, Trader Talk

Add Your Comment